Frontiers in Neurology (Mar 2021)

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis

  • Emilio Portaccio,
  • Emilio Portaccio,
  • Angelo Bellinvia,
  • Elio Prestipino,
  • Benedetta Nacmias,
  • Benedetta Nacmias,
  • Silvia Bagnoli,
  • Lorenzo Razzolini,
  • Luisa Pastò,
  • Claudia Niccolai,
  • Benedetta Goretti,
  • Mattia Fonderico,
  • Giovanni Bosco Zimatore,
  • Nunzia Alessandra Losignore,
  • Sandro Sorbi,
  • Sandro Sorbi,
  • Maria Pia Amato,
  • Maria Pia Amato

DOI
https://doi.org/10.3389/fneur.2021.645220
Journal volume & issue
Vol. 12

Abstract

Read online

Introduction: Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, involved in neuronal survival and synaptic plasticity. The BDNF Val66Met polymorphism is known to reduce BDNF expression and secretion; its role in multiple sclerosis (MS) is poorly investigated.Objectives and Methods: In this multicenter, retrospective study, we assessed the role of BDNF Val66Met polymorphism on cognitive and motor disability in MS patients consecutively referred to the University of Florence and the Hospital of Barletta. All patients underwent a genetic analysis for the presence of Val66Met polymorphism and a comprehensive neuropsychological examination on the Rao's Brief Repeatable Battery and the Stroop Color Word Test. Possible predictors of the Expanded Disability Status Scale (EDSS) score and number of failed neuropsychological tests were assessed through linear multivariable regression models.Results: Ninety-eight patients were recruited. Patients with the BDNF Val66Met polymorphism (35.7%) were more frequently males (p = 0.020), more disabled (p = 0.026) and, marginally, older (p = 0.064). In the multivariable analysis, BDNF Val66Met polymorphism was associated with a better cognitive performance (B = −1.1 ± 0.5, p = 0.027). Higher EDSS score was associated with a progressive disease course (B = 3.4, p < 0.001) and, marginally, with the presence of the BDNF Val66Met polymorphism (B = 0.56, p = 0.066).Discussion: Our results preliminarily suggest a protective role of BDNF Val66Met polymorphism against cognitive impairment in MS patients, possibly related to a detrimental effect of increased BDNF concentration in a neuroinflammatory environment.

Keywords